CRISPR Therapeutics AG - Common Shares (CRSP)

$44.98 0.47 (1.04%)

14:35 EST CRSP Stock Quote Delayed 30 Minutes

3 Cutting-Edge Healthcare Stocks That Can Pay Off Big Time

By John Blankenhorn, InvestorPlace Contributor Mar 18, 2023

For investors betting on healthcare, look for these three companies to provide the treatments of tomorrow.

7 Cathie Wood Stocks for Your March Buy List

3 CRISPR Gene Editing Stocks to Consider for Ground-Floor Investing

3 CRISPR Stocks to Buy Now Or You’ll Be Kicking Yourself Later

Volume:

Previous Close -

Market Cap 3.55B

PE Ratio -10.34

EPS -4.35

Volume (Avg. Vol.) 775,115

Day's Range $44.25 - $46.00

52-Week Range $36.52 - $90.62

Dividend & Yield N/A (N/A)

CRSP Stock Predictions, Articles, and CRISPR Therapeutics AG - Common Shares News

7 CRISPR Stocks With the Best Long-Term Potential

By Alex Sirois, InvestorPlace Contributor Jan 30, 2023

CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve.

3 Gene Editing Stocks to Buy Now OR You’ll Be Kicking Yourself Later

By Chris Markoch, InvestorPlace Contributor Jan 25, 2023

Even in a risk-off market, gene editing stocks look attractive. Here are three stocks that may be worth a closer look at this time.

3 Gene Editing Stocks With the Best Long-Term Potential

By Muslim Farooque, InvestorPlace Contributor Jan 25, 2023

These gene editing stocks are likely to deliver massive gains ahead in the fast-evolving biotech space

7 Biotech Stocks That Will Make You Rich in 10 Years

By Josh Enomoto, InvestorPlace Contributor Jan 18, 2023

Although the health innovation space presents risks, the opportunities beckon a look at the biotech stocks that will make you rich in 10 years.

3 CRISPR Stocks That Will Make You Filthy Rich in 10 Years

By Ian Cooper, InvestorPlace Contributor Jan 18, 2023

CRISPR could be revolutionary, leading us to put together this list of CRISPR stocks that will make you rich in ten years.

7 Stocks to Add to Your 10x Watchlist

By Chris Markoch, InvestorPlace Contributor Dec 16, 2022

It’s always a good time to look for stocks with exceptional growth potential. Here are seven 10x stocks for your watchlist

The Top 5 Stocks Cathie Wood Bought and Sold This Week

By Eddie Pan, InvestorPlace Financial News Writer Oct 21, 2022

Cathie Wood's flagship ETF, the ARK Innovation ETF, hit a five-year and 52-week low this week, casting doubts on the investment manager.

Why Is Crispr Therapeutics (CRSP) Stock Up Today?

By William White, InvestorPlace Writer Sep 27, 2022

Crispr Therapeutics (CRSP) stock is gaining on Tuesday after the FDA granted exagamglogene autotemcel (exa-cel) a rolling review.

The 7 Best Biotech Stocks to Buy

By Dana Blankenhorn, InvestorPlace Contributor Sep 20, 2022

The best biotech stocks to buy are a lot like the best computer stocks 40 years ago; the biggest similarity is how hard they are to predict.

7 Cathie Wood Stocks to Buy on the Dip

By Alex Sirois, InvestorPlace Contributor Aug 22, 2022

Cathie Wood stocks lost some of their shine in the tech wreck. But the second half of 2022 looks much brighter for these picks.

5 Cathie Wood Stocks Signaling “The Bear Market Is Over”

By Thomas Yeung, CFA, InvestorPlace Markets Analyst Aug 22, 2022

These top Cathie Wood stocks are signalling that the bear market is over. For savvy investors, that presents a chance to profit.

Why Are Gene Editing Stocks NTLA, ALNY, CRSP, BEAM Up Today?

By Shrey Dua, InvestorPlace Senior Financial News Reporter Aug 3, 2022

Gene editing stocks are a bright spot on the market today after Alnylam announced the success of one of its RNAi therapies, Patisiran.

7 No-Brainer Biotech Stocks to Add to Your Buy List

By Josh Enomoto, InvestorPlace Contributor Jun 9, 2022

With the broader markets grumbling, investors should consider biotech stocks to buy for their permanently relevant profile.

5 Cathie Wood Stocks to Buy Now

By Tezcan Gecgil, InvestorPlace Contributor May 16, 2022

ARK Invest funds led by Cathie Wood seek long-term capital growth and focus mainly on disruptive innovation. Here's a look a five related stocks to consider.

3 Cathie Wood Stocks to Count on in Q2

By Muslim Farooque, InvestorPlace Contributor Apr 26, 2022

These Cathie Wood Stocks have their risks but offer a massive upside potential ahead

7 Potential Biotech Stocks Buyout Targets in 2022

By Shanthi Rexaline Apr 21, 2022

Big biopharma companies usually rely on M&A to get immediate access to a new class of drug or technology, fill in the gap in their pipeline and compensate for revenue loss from patent expiration of blockbuster products.

3 Best Stocks to Trade Right Now

By Chris Tyler, InvestorPlace Contributor Mar 24, 2022

Get past the persistently bearish headlines, and you'll find stocks to trade long in emerging bull markets that could be lucrative.

3 Ark Invest Most-Shorted Stocks to Buy

By Chris Tyler, InvestorPlace Contributor Mar 11, 2022

These most-shorted stocks have investors seeing red, but there is a silver lining that's playing out on the price chart for today's buyers.

3 Cathie Wood Stocks to Buy

By Chris Tyler, InvestorPlace Contributor Mar 9, 2022

Don't buy Cathie Wood stocks because the market was singing on Wednesday, purchase them because of a much bigger and bullish picture.

Peloton Isn’t the ONLY Takeover Target. What Companies Could Be Bought Out in 2022?

By Tezcan Gecgil, InvestorPlace Contributor Feb 23, 2022

Savvy investors can generate lucrative returns by investing in companies that look like prime takeover targets. This article speculates on a number of takeover targets of 2022.

CRISPR Therapeutics AG - Common Shares (CRSP)

3 Cutting-Edge Healthcare Stocks That Can Pay Off Big Time

7 Cathie Wood Stocks for Your March Buy List

3 CRISPR Gene Editing Stocks to Consider for Ground-Floor Investing

3 CRISPR Stocks to Buy Now Or You’ll Be Kicking Yourself Later

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

CRISPR Therapeutics AG - Common Shares (CRSP)

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

CRSP Stock Predictions, Articles, and CRISPR Therapeutics AG - Common Shares News

Subscriber Sign in